Cell therapy weekly: First stem cell drug application approved in China for Phase II clinical trial
This week: Gamida Cell (Jerusalem, Israel) and Be The Match BioTherapies (MN, USA) will collaborate to improve patient outcomes for those undergoing bone marrow transplants and Athersys (OH, USA) announces positive results from expletory clinical study of MultiStem® cell therapy.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>